vs
Nutex Health, Inc.（NUTX）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Nutex Health, Inc.的1.3倍（$197.9M vs $151.7M），Nutex Health, Inc.净利率更高（7.8% vs 6.7%，领先1.1%），REPLIGEN CORP同比增速更快（13.6% vs -41.1%），Nutex Health, Inc.自由现金流更多（$69.0M vs $17.6M），过去两年Nutex Health, Inc.的营收复合增速更高（50.0% vs 14.4%）
Nutex Health是一家总部位于美国得克萨斯州休斯敦的营利性医疗企业，核心业务为运营各类医疗机构，是美国本土医疗领域的专业运营机构，致力于为当地市场提供相关医疗服务与场地运营支持。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
NUTX vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.3倍
$151.7M
营收增速更快
RGEN
高出54.8%
-41.1%
净利率更高
NUTX
高出1.1%
6.7%
自由现金流更多
NUTX
多$51.4M
$17.6M
两年增速更快
NUTX
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $197.9M |
| 净利润 | $11.8M | $13.3M |
| 毛利率 | 30.4% | 52.5% |
| 营业利润率 | 20.4% | 9.0% |
| 净利率 | 7.8% | 6.7% |
| 营收同比 | -41.1% | 13.6% |
| 净利润同比 | -80.8% | 143.9% |
| 每股收益（稀释后） | $2.34 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NUTXRGEN
| Q4 25 | $151.7M | $197.9M | ||
| Q3 25 | $267.8M | $188.8M | ||
| Q2 25 | $244.0M | $182.4M | ||
| Q1 25 | $211.8M | $169.2M | ||
| Q4 24 | $257.6M | $174.1M | ||
| Q3 24 | $78.8M | $154.9M | ||
| Q2 24 | $76.1M | $154.1M | ||
| Q1 24 | $67.5M | $151.3M |
净利润NUTXRGEN
| Q4 25 | $11.8M | $13.3M | ||
| Q3 25 | $55.4M | $14.9M | ||
| Q2 25 | $-17.7M | $14.9M | ||
| Q1 25 | $21.2M | $5.8M | ||
| Q4 24 | $61.6M | $-30.3M | ||
| Q3 24 | $-8.8M | $-654.0K | ||
| Q2 24 | $-364.0K | $3.3M | ||
| Q1 24 | $-364.0K | $2.1M |
毛利率NUTXRGEN
| Q4 25 | 30.4% | 52.5% | ||
| Q3 25 | 57.8% | 53.2% | ||
| Q2 25 | 51.2% | 50.0% | ||
| Q1 25 | 55.9% | 53.6% | ||
| Q4 24 | 55.0% | 26.1% | ||
| Q3 24 | 27.8% | 50.0% | ||
| Q2 24 | 29.7% | 49.8% | ||
| Q1 24 | 15.1% | 49.5% |
营业利润率NUTXRGEN
| Q4 25 | 20.4% | 9.0% | ||
| Q3 25 | 48.7% | 8.9% | ||
| Q2 25 | 13.8% | 7.6% | ||
| Q1 25 | 38.1% | 3.9% | ||
| Q4 24 | 44.4% | -17.7% | ||
| Q3 24 | 12.3% | -5.1% | ||
| Q2 24 | 7.0% | 1.0% | ||
| Q1 24 | 2.1% | 1.3% |
净利率NUTXRGEN
| Q4 25 | 7.8% | 6.7% | ||
| Q3 25 | 20.7% | 7.9% | ||
| Q2 25 | -7.3% | 8.2% | ||
| Q1 25 | 10.0% | 3.4% | ||
| Q4 24 | 23.9% | -17.4% | ||
| Q3 24 | -11.2% | -0.4% | ||
| Q2 24 | -0.5% | 2.2% | ||
| Q1 24 | -0.5% | 1.4% |
每股收益（稀释后）NUTXRGEN
| Q4 25 | $2.34 | $0.24 | ||
| Q3 25 | $7.76 | $0.26 | ||
| Q2 25 | $-2.95 | $0.26 | ||
| Q1 25 | $3.33 | $0.10 | ||
| Q4 24 | $11.56 | $-0.55 | ||
| Q3 24 | $-1.72 | $-0.01 | ||
| Q2 24 | $-0.07 | $0.06 | ||
| Q1 24 | $-0.08 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $185.6M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $329.4M | $2.1B |
| 总资产 | $918.5M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资NUTXRGEN
| Q4 25 | $185.6M | $767.6M | ||
| Q3 25 | $166.0M | $748.7M | ||
| Q2 25 | $96.7M | $708.9M | ||
| Q1 25 | $84.7M | $697.2M | ||
| Q4 24 | $40.6M | $757.4M | ||
| Q3 24 | $46.9M | $784.0M | ||
| Q2 24 | $40.8M | $809.1M | ||
| Q1 24 | $30.0M | $780.6M |
总债务NUTXRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NUTXRGEN
| Q4 25 | $329.4M | $2.1B | ||
| Q3 25 | $317.2M | $2.1B | ||
| Q2 25 | $235.3M | $2.1B | ||
| Q1 25 | $176.9M | $2.0B | ||
| Q4 24 | $132.4M | $2.0B | ||
| Q3 24 | $60.4M | $2.0B | ||
| Q2 24 | $62.7M | $2.0B | ||
| Q1 24 | $63.0M | $2.0B |
总资产NUTXRGEN
| Q4 25 | $918.5M | $2.9B | ||
| Q3 25 | $964.5M | $2.9B | ||
| Q2 25 | $841.0M | $2.9B | ||
| Q1 25 | $761.9M | $2.9B | ||
| Q4 24 | $655.3M | $2.8B | ||
| Q3 24 | $438.5M | $2.8B | ||
| Q2 24 | $422.4M | $2.9B | ||
| Q1 24 | $404.3M | $2.8B |
负债/权益比NUTXRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.4M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $69.0M | $17.6M |
| 自由现金流率自由现金流/营收 | 45.5% | 8.9% |
| 资本支出强度资本支出/营收 | 0.9% | 4.1% |
| 现金转化率经营现金流/净利润 | 5.95× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $245.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流NUTXRGEN
| Q4 25 | $70.4M | $25.7M | ||
| Q3 25 | $99.5M | $48.1M | ||
| Q2 25 | $27.3M | $28.6M | ||
| Q1 25 | $51.0M | $15.0M | ||
| Q4 24 | $54.0K | $39.2M | ||
| Q3 24 | $6.8M | $49.3M | ||
| Q2 24 | $13.3M | $42.2M | ||
| Q1 24 | $3.1M | $44.7M |
自由现金流NUTXRGEN
| Q4 25 | $69.0M | $17.6M | ||
| Q3 25 | $99.2M | $43.4M | ||
| Q2 25 | $26.5M | $21.5M | ||
| Q1 25 | $50.9M | $11.4M | ||
| Q4 24 | $-341.0K | $33.6M | ||
| Q3 24 | $6.2M | $42.3M | ||
| Q2 24 | $12.7M | $37.4M | ||
| Q1 24 | $2.3M | $36.4M |
自由现金流率NUTXRGEN
| Q4 25 | 45.5% | 8.9% | ||
| Q3 25 | 37.0% | 23.0% | ||
| Q2 25 | 10.9% | 11.8% | ||
| Q1 25 | 24.0% | 6.8% | ||
| Q4 24 | -0.1% | 19.3% | ||
| Q3 24 | 7.8% | 27.3% | ||
| Q2 24 | 16.7% | 24.3% | ||
| Q1 24 | 3.4% | 24.0% |
资本支出强度NUTXRGEN
| Q4 25 | 0.9% | 4.1% | ||
| Q3 25 | 0.1% | 2.5% | ||
| Q2 25 | 0.3% | 3.9% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.2% | 3.2% | ||
| Q3 24 | 0.8% | 4.5% | ||
| Q2 24 | 0.7% | 3.1% | ||
| Q1 24 | 1.1% | 5.5% |
现金转化率NUTXRGEN
| Q4 25 | 5.95× | 1.93× | ||
| Q3 25 | 1.80× | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | 2.40× | 2.57× | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
RGEN
暂无分部数据
